Travere Therapeutics

SMART trial results presented at Kidney Week 2024 show semaglutide reduces UACR by -52.1% in nondiabetic CKD patients, with sustained effects post-treatment. No significant Cr-eGFR difference observed, but weight and waist circumference reduced. Study explores semaglutide's potential in kidney and cardiovascular care.

Travere Therapeutics presented new data on FILSPARI (sparsentan) at ASN Kidney Week 2024, showing its effectiveness in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Key findings include rapid and sustained proteinuria reduction, significant complete remission rates in IgAN patients, and safety in combination therapies. The data also highlighted long-term kidney health benefits in genetic, treatment-resistant FSGS patients.

Iptacopan (Fabhalta) showed a clinically meaningful reduction in proteinuria and confirmed clinical benefit of alternative pathway inhibition in IgA nephropathy, with a 38.3% lower UPCR than placebo by month 9. The study also found significant decreases in complement pathway biomarkers, supporting selective alternative pathway inhibition.

Travere Therapeutics presented new data at ASN Kidney Week 2024 showing FILSPARI (sparsentan) effective in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), with nearly 60% of IgAN patients achieving complete remission. Data also highlighted safety and efficacy in combination therapies and rapid, sustained proteinuria reduction in genetic FSGS patients.

Kidney Compass, hosted by Brendon Neuen and Shikha Wadhwani, aims to simplify nephrology and clinical trials. The inaugural episode discusses their backgrounds, motivations, and key topics like glomerular disease and diabetic kidney disease. Future episodes will explore deeper aspects of nephrology research.

Swissmedic grants temporary marketing authorization for FILSPARI, a treatment for primary IgA nephropathy, based on results from the Phase 3 PROTECT Trial. FILSPARI offers a once-daily, oral, non-immunosuppressive treatment, potentially replacing RASi in patients with IgAN.

Swissmedic grants Travere Therapeutics and CSL Vifor temporary marketing authorization for FILSPARI in treating primary IgA nephropathy with high urine protein levels, following FDA and EMA approvals.

Swissmedic grants temporary marketing authorization for FILSPARI, a treatment for primary IgA nephropathy, based on the PROTECT trial results. CSL Vifor and Travere Therapeutics anticipate providing access to this innovative therapy in Switzerland.